Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.73 |
| ▸ | ANPEP | P15144 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302698 | 0.95 | EPHX1 (0.73) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL20466361 | 0.95 | EPHX1 (0.73) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL9182651 | 0.93 | EPHX1 (0.70) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL15476621 | 0.90 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL2736189 | 0.90 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL902607 | 0.90 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL902633 | 0.90 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL18034347 | 0.90 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL3127068 | 0.90 | EPHX1 (0.59) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL10202821 | 0.89 | EPHX1 (0.64) | EPHX1ANPEPSLC6A2TAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7312244-B2 | Polyamine analog-amino acid conjugates useful as anticancer agents | CELLGATE, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186825-B2 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1698629-A2 | Polyamines and their use in therapy | Cellgate, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050233943-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1337504-A4 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | CELLGATE INC (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040235962-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6794545-B1 | INCREASES IN THE POLYAMINE POOL SUPPRESS POLYAMINE BIOSYNTHESIS ALSO INHIBIT CELL GROWTH; ANTIPROLIFERATIVE AGENT | SLIL BIOMEDICAL CORPORATION | 2004-09-21 | — | — | US | disclosed |
| US-20040133013-A1 | Novel polyamine analog-amino acid conjugates useful as anticancer agents | CELLGATE, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | SLIL BIOMEDICAL CORPORATION (US) | 2004-01-08 | — | — | US | disclosed |
| US-6649587-B1 | Cytostatic or cytocidal componenet conjugated to a polypeptide recognized and cleaved by enzymes such as prostate specific antigen (PSA) and cathepsin B | SLIL BIOMEDICAL CORPORATION | 2003-11-18 | — | — | US | disclosed |
| EP-1337504-A2 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | Slil Biomedical Corporation (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002091989-A2 | ANTIVIRAL THERAPIES USING POLYAMINE OR POLYAMINE ANALOG-AMINO ACID CONJUGATES | SLIL BIOMEDICAL CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002038105-A2 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | SLIL BIOMEDICAL CORPORATION (US) | 2002-05-16 | — | — | WO | disclosed |
| EP-1173223-A2 | CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | Slil Biomedical Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066175-A2 | CONJUGATES AS THERAPIES FOR CANCER AND PROSTATE DISEASES | SLIL BIOMEDICAL CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235962-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | EPHX1 2426/4885ANPEP 716/4885SLC6A2 1532/4885 |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | EPHX1 2426/4885ANPEP 716/4885SLC6A2 1532/4885 |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CTSB, CTSL, CTSV | EPHX1 1504/4885ANPEP 69/4885SLC6A2 2035/4885 |
| US-20040133013-A1 | Novel polyamine analog-amino acid conjugates useful as anticancer agents | SLC7A1, SRM, PAICS | EPHX1 3270/4885ANPEP 154/4885SLC6A2 1194/4885 |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, KLK3, FOLH1 | EPHX1 1945/4885ANPEP 60/4885SLC6A2 1848/4885 |
| US-20050233943-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CTSB, CTSL, CTSV | EPHX1 1504/4885ANPEP 69/4885SLC6A2 2035/4885 |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | EPHX1 1504/4885ANPEP 69/4885SLC6A2 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.